U. Nestle et al., F-18-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: High impact in patients with atelectasis, INT J RAD O, 44(3), 1999, pp. 593-597
Citations number
20
Categorie Soggetti
Radiology ,Nuclear Medicine & Imaging","Onconogenesis & Cancer Research
Journal title
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Purpose: F-18-deoxyglucose positron emission tomography (FDG-PET) is increa
singly applied in the staging of lung cancer (LC). This study analyzes the
potential contribution of PET in radiotherapy planning for LC with special
respect to tumor-associated atelectasis.
Methods and Materials: Thirty-four patients with histologically confirmed L
C, who had been examined by PET during pretreatment staging, were included.
All were irradiated after CT-based therapy planning with anterior/posterio
r (AP) portals encompassing the primary tumor and the mediastinum (CT porta
ls, CP). The result of the PET examination was unknown in treatment plannin
g. In retrospect, a PET portal (PP) was delineated and compared with the CP
.
Results: In 12/34 cases, the shape and/or size of the portals were changed,
primarily (n = 10) the size of the fields was reduced. The median area of
CP was 182 cm(2) versus 167 cm(2) of PP. Seventeen of 34 patients had dys-
or atelectasis caused by a central primary tumor. In these cases, differenc
es between CP and PP were significantly more frequent than in the other pat
ients (8/17 vs. 3/17, p = 0.03).
Conclusion: In this retrospective analysis, the information provided by FDG
-PET would have contributed to a substantial reduction of the size of radio
therapy portals. This applies particularly for patients with tumor-associat
ed dys- or atelectasis. (C) 1999 Elsevier Science Inc.